March 09, 2023 — 09:28 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - InVivo Therapeutics Holdings Corp. (NVIV) said that INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of the company's investigational Neuro-Spinal Scaffold, did not achieve primary endpoint of defined improvement on standard impairment scale.
Neuro-Spinal Scaffold is a bioresorbable scaffold-based device in development for patients with acute spinal cord injuries.
The company noted that it will conduct a full assessment of the study data set and plans to share its findings in full in a peer-reviewed medical venue at a later date. The company will also evaluate its strategic options and provide an update on corporate direction when appropriate.
For More Such Health News, visit rttnews.com 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.